GE Healthcare has recently introduced its first made-in-India artificial intelligence (AI) enabled cath lab diagnostic imaging platform, the Optima IGS 320. This sophisticated interventional cardiology system will guide non-invasive cardiovascular procedures with better precision and versatility, says GlobalData, a leading data and analytics company.

GlobalData forecasts the Indian cardiovascular devices market to grow at a compound annual growth rate of 5% between 2022 and 2030. Research and development of advanced technologies are expected to further drive the market.

Shachee Singh, Medical Devices Analyst at GlobalData, comments: “Cardiovascular disorders (CVD) are becoming more prevalent in India, highlighting the need for affordable technology to match the rising demand for less invasive procedures. Products such as the Optima IGS 320 will support personalized treatment regimens for patients, with greater accuracy through automation of intricate cardiac and electrophysiology operations and intelligent imaging.”

GE Healthcare claims that Optima IGS 320 is a cost-effective visualization and imaging system with built-in neural-network-based AutoRight technology that can optimize dose settings in real time. Features such as the PCI ASSIST will enhance the quality of images during risky procedures and make it an ideal solution for complex cardiac treatment interventions.

Singh concludes: “With a shift in disease patterns and a rise in CVD incidence among the younger population of the country, quality cardiac care requires innovative healthcare solutions. Automated cath labs will reduce the workload of cardiologists and allow them to focus on providing better patient care.”